<!DOCTYPE html>
<!-- Generated by pkgdown: do not edit by hand --><html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title> • RE-Test-Reports</title>
<script src="../deps/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="../deps/bootstrap-5.3.1/bootstrap.min.css" rel="stylesheet">
<script src="../deps/bootstrap-5.3.1/bootstrap.bundle.min.js"></script><link href="../deps/font-awesome-6.5.2/css/all.min.css" rel="stylesheet">
<link href="../deps/font-awesome-6.5.2/css/v4-shims.min.css" rel="stylesheet">
<script src="../deps/headroom-0.11.0/headroom.min.js"></script><script src="../deps/headroom-0.11.0/jQuery.headroom.min.js"></script><script src="../deps/bootstrap-toc-1.0.1/bootstrap-toc.min.js"></script><script src="../deps/clipboard.js-2.0.11/clipboard.min.js"></script><script src="../deps/search-1.0.0/autocomplete.jquery.min.js"></script><script src="../deps/search-1.0.0/fuse.min.js"></script><script src="../deps/search-1.0.0/mark.min.js"></script><!-- pkgdown --><script src="../pkgdown.js"></script><meta property="og:title" content="">
</head>
<body>
    <a href="#main" class="visually-hidden-focusable">Skip to contents</a>


    <nav class="navbar navbar-expand-lg fixed-top bg-light" data-bs-theme="light" aria-label="Site navigation"><div class="container">

    <a class="navbar-brand me-2" href="../index.html">RE-Test-Reports</a>

    <small class="nav-text text-muted me-auto" data-bs-toggle="tooltip" data-bs-placement="bottom" title="">0.0.0.9000</small>


    <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#navbar" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>

    <div id="navbar" class="collapse navbar-collapse ms-3">
      <ul class="navbar-nav me-auto">
<li class="nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-reports">
<li><a class="dropdown-item" href="../articles/Aciclovir-Mean.html">Aciclovir-Mean</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Mean-SVG.html">Aciclovir-Mean-SVG</a></li>
    <li><a class="dropdown-item" href="../articles/Aciclovir-Population.html">Aciclovir-Population</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Absorption.html">Raltegravir-Absorption</a></li>
    <li><a class="dropdown-item" href="../articles/Raltegravir-Mass-Balance.html">Raltegravir-Mass-Balance</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO7.html">Test-NO7</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO8.html">Test-NO8</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO9.html">Test-NO9</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO10.html">Test-NO10</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO11.html">Test-NO11</a></li>
    <li><a class="dropdown-item" href="../articles/Test-NO12.html">Test-NO12</a></li>
  </ul>
</li>
<li class="active nav-item dropdown">
  <button class="nav-link dropdown-toggle" type="button" id="dropdown-qualification-reports" data-bs-toggle="dropdown" aria-expanded="false" aria-haspopup="true">Qualification Reports</button>
  <ul class="dropdown-menu" aria-labelledby="dropdown-qualification-reports">
<li><a class="dropdown-item" href="../articles/Qualification-CKD.html">Qualification-CKD</a></li>
    <li><a class="dropdown-item" href="../articles/Qualification-HI.html">Qualification-HI</a></li>
    <li><a class="dropdown-item" href="../articles/Pediatric_Qualification_Package_UGT1A1_Ontogeny.html">Pediatric_Qualification_Package_UGT1A1_Ontogeny</a></li>
    <li><a class="dropdown-item" href="../articles/Digoxin-Model.html">Digoxin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Propofol-Model.html">Propofol-Model</a></li>
    <li><a class="dropdown-item" href="../articles/dAb2-Model.html">dAb2-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524YTE-Model.html">MEDI524YTE-Model</a></li>
    <li><a class="dropdown-item" href="../articles/MEDI524-Model.html">MEDI524-Model</a></li>
    <li><a class="dropdown-item" href="../articles/7E3-Model.html">7E3-Model</a></li>
    <li><a class="dropdown-item" href="../articles/CDA1-Model.html">CDA1-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Inulin-Model.html">Inulin-Model</a></li>
    <li><a class="dropdown-item" href="../articles/BAY794620-Model.html">BAY794620-Model</a></li>
    <li><a class="dropdown-item" href="../articles/Tefibazumab-Model.html">Tefibazumab-Model</a></li>
    <li><a class="dropdown-item" href="../articles/TestInput01_DDI.html">TestInput01_DDI</a></li>
  </ul>
</li>
      </ul>
<ul class="navbar-nav">
<li class="nav-item"><form class="form-inline" role="search">
 <input class="form-control" type="search" name="search-input" id="search-input" autocomplete="off" aria-label="Search site" placeholder="Search for" data-search-index="../search.json">
</form></li>
      </ul>
</div>


  </div>
</nav><div class="container template-article">




<div class="row">
  <main id="main" class="col-md-9"><div class="page-header">

      <h1></h1>
            
      

      <div class="d-none name"><code>BAY794620-Model.Rmd</code></div>
    </div>

    
    
<div class="section level2">
<h2 id="building-and-evaluation-of-a-pbpk-model-for-bay-79-4620-in-mice">Building and evaluation of a PBPK model for BAY 79-4620 in mice<a class="anchor" aria-label="anchor" href="#building-and-evaluation-of-a-pbpk-model-for-bay-79-4620-in-mice"></a>
</h2>
<table class="table">
<colgroup>
<col width="43%">
<col width="56%">
</colgroup>
<thead><tr class="header">
<th>Version</th>
<th>1.0-OSP11.0</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>based on <em>Model Snapshot</em> and <em>Evaluation Plan</em>
</td>
<td><a href="https://github.com/Open-Systems-Pharmacology/BAY794620-Model/releases/tag/v1.0" class="external-link uri">https://github.com/Open-Systems-Pharmacology/BAY794620-Model/releases/tag/v1.0</a></td>
</tr>
<tr class="even">
<td>OSP Version</td>
<td>11.0</td>
</tr>
<tr class="odd">
<td>Qualification Framework Version</td>
<td>3.0</td>
</tr>
</tbody>
</table>
<p>This evaluation report and the corresponding PK-Sim project file are
filed at:</p>
<p><a href="https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/" class="external-link uri">https://github.com/Open-Systems-Pharmacology/OSP-PBPK-Model-Library/</a></p>
</div>
<div class="section level2">
<h2 id="table-of-contents">Table of Contents<a class="anchor" aria-label="anchor" href="#table-of-contents"></a>
</h2>
<ul>
<li><a href="#introduction">1 Introduction</a></li>
<li>
<a href="#methods">2 Methods</a>
<ul>
<li><a href="#modeling-strategy">2.1 Modeling Strategy</a></li>
<li>
<a href="#methods-data">2.2 Data</a>
<ul>
<li><a href="#invitro-and-physico-chemical-data">2.2.1 In vitro /
physico-chemical Data</a></li>
<li>
<a href="#PK-data">2.2.2 PK Data </a><a id="PK-data"></a>
</li>
</ul>
</li>
<li><a href="#model-parameters-and-assumptions">2.3 Model Parameters and
Assumptions</a></li>
</ul>
</li>
<li>
<a href="#results-and-discussion">3 Results and Discussion</a>
<ul>
<li><a href="#final-input-parameters">3.1 Final input
parameters</a></li>
<li><a href="#diagnostics-plots">3.2 Diagnostics Plots</a></li>
<li><a href="#ct-profiles">3.3 Concentration-Time Profiles</a></li>
</ul>
</li>
<li><a href="#conclusion">4 Conclusion</a></li>
<li><a href="#main-references">5 References</a></li>
</ul>
</div>
<div class="section level2">
<h2 id="introduction">1 Introduction<a id="introduction"></a><a class="anchor" aria-label="anchor" href="#introduction"></a>
</h2>
<p>BAY 79-4620 is an antibody–drug conjugate consisting of a human IgG1
mAb directed against human carbonic anhydrase IX (CA IX) conjugated to
the toxophore monomethylauristatin E (MMAE) via a valine-citrulline
based linker (<a href="#id_5-references">Petrul 2012</a>).</p>
<p>For BAY 79-4620, tissue concentration-time profiles for a large
number of different mice tissues were measured and used together with
pharmacokinetic (PK) data from 5 other compounds to identify unknown
parameters during the development of the generic large molecule
physiologically based pharmacokinetic (PBPK) model in PK-Sim (<a href="#id_5-references">Niederalt 2018</a>).</p>
<p>The herein presented evaluation report evaluates the performance of a
PBPK model for BAY 79-4620 in xenograft mice for the PK data used for
the development of the generic large molecule model in PK-Sim. A
standard PK-Sim model was used without an additional tumor organ and
without target mediated drug disposition effects from CA IX binding in
the tumor - in contrast to the model which has been used in Ref. (<a href="#id_5-references">Niederalt 2018</a>).</p>
<p>The presented BAY 79-4620 PBPK model as well as the respective
evaluation plan and evaluation report are provided open-source (<a href="https://github.com/Open-Systems-Pharmacology/BAY794620-Model" class="external-link uri">https://github.com/Open-Systems-Pharmacology/BAY794620-Model</a>).</p>
</div>
<div class="section level2">
<h2 id="methods">2 Methods<a id="methods"></a><a class="anchor" aria-label="anchor" href="#methods"></a>
</h2>
<div class="section level3">
<h3 id="modeling-strategy">2.1 Modeling Strategy<a id="modeling-strategy"></a><a class="anchor" aria-label="anchor" href="#modeling-strategy"></a>
</h3>
<p>The development of the large molecule PBPK model in PK-Sim® has
previously been described by Niederalt et al. (<a href="#id_5-references">Niederalt 2018</a>). In short, the model was
built as an extension of the PK-Sim® model for small molecules
incorporating (i) the two-pore formalism for drug extravasation from
blood plasma to interstitial space, (ii) lymph flow, (iii) endosomal
clearance and (iv) protection from endosomal clearance by neonatal Fc
receptor (FcRn) mediated recycling.</p>
<p>For model development and evaluation, PK data were used from
compounds with a wide range of solute radii and from different species.
The PK data used for parameter estimation were from the following
compounds: antibody–drug conjugate BAY 79-4620 in mice (Bayer in house
data), antibody 7E3 in wild-type and FcRn knockout mice (<a href="#id_5-references">Garg 2007</a>, <a href="#id_5-references">Garg2009</a>), domain antibody dAb2 in mice (<a href="#id_5-references">Sepp 2015</a>), antibodies MEDI-524 and
MEDI-524-YTE in monkeys (<a href="#id_5-references">Dall’Acqua
2006</a>), and antibody CDA1 in humans (<a href="#id_5-references">Taylor 2008</a>). The PK data used for model
evaluation were from inulin in rats (<a href="#id_5-references">Tsuji1983</a>) and tefibazumab in humans (<a href="#id_5-references">Reilly 2005</a>).</p>
<p>The PBPK model including the estimated physiological parameters as
described by Niederalt et al. (<a href="#id_5-references">Niederalt
2018</a>) is available in the Open Systems Pharmacology Suite from
version 7.1 onwards.</p>
<p>This evaluation report focuses on the PBPK model for the
antibody–drug conjugate BAY 79-4620.</p>
<p>Details about input data (physicochemical, <em>in vitro</em> and PK)
can be found in <a href="#id_22-data">Section 2.2</a>.</p>
<p>Details about the structural model and its parameters can be found in
<a href="#id_23-model-parameters-and-assumptions">Section 2.3</a>.</p>
</div>
<div class="section level3">
<h3 id="data">2.2 Data<a id="methods-data"></a><a class="anchor" aria-label="anchor" href="#data"></a>
</h3>
<div class="section level4">
<h4 id="in-vitro-physico-chemical-data">2.2.1 In vitro / physico-chemical Data
<a id="invitro-and-physico-chemical-data"></a><a class="anchor" aria-label="anchor" href="#in-vitro-physico-chemical-data"></a>
</h4>
<p>A literature search was performed to collect available information on
physicochemical properties of BAY 79-4620. The obtained information from
literature is summarized in the table below.</p>
<table class="table">
<colgroup>
<col width="11%">
<col width="6%">
<col width="7%">
<col width="23%">
<col width="50%">
</colgroup>
<thead><tr class="header">
<th align="left"><strong>Parameter</strong></th>
<th><strong>Unit</strong></th>
<th><strong>Value</strong></th>
<th>Source</th>
<th><strong>Description</strong></th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">MW</td>
<td>g/mol</td>
<td>152000</td>
<td>Bayer in-house data</td>
<td>Molecular weight</td>
</tr>
<tr class="even">
<td align="left">r</td>
<td>nm</td>
<td>5.34</td>
<td><a href="#id_5-references">Taylor 1984</a></td>
<td>Hydrodynamic solute radius</td>
</tr>
<tr class="odd">
<td align="left">Kd (FcRn)</td>
<td>µM</td>
<td>0.082</td>
<td><a href="#id_5-references">Zhou 2003</a></td>
<td>Dissociation constant for binding of a humane IgG1 antibody to
murine FcRn at pH 6</td>
</tr>
</tbody>
</table>
</div>
<div class="section level4">
<h4 id="pk-data">2.2.2 PK Data <a id="PK-data"></a><a class="anchor" aria-label="anchor" href="#pk-data"></a>
</h4>
<p>The biodistribution data from mice for BAY 79-4620 were Bayer AG in
house data taken from two studies:</p>
<table class="table">
<colgroup>
<col width="31%">
<col width="68%">
</colgroup>
<thead><tr class="header">
<th align="left">Data</th>
<th align="left">Description</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">Whole-body autoradiography</td>
<td align="left">Female nude mice (NMRI nu/nu), bearing HT-29 human
colon carcinoma xenografts, were dosed intravenously with 1.25 mg/kg
body weight of 125I-labeled BAY 79-4620. The distribution of total
radioactivity in organs and tissues was determined by quantitative
whole-body autoradiography after sacrificing the mice (two per time) at
various time points after administration.</td>
</tr>
<tr class="even">
<td align="left">Wet-tissue dissection study</td>
<td align="left">Female nude mice (NMRI nu/nu), bearing HT-29 human
colon carcinoma xenografts, were dosed intravenously with 2 µCi (approx.
500 ng) of 125I-labeled BAY 79-4620. The distribution of total
radioactivity in organs and tissues was determined after sacrificing the
mice (three per time) and dissection of the organs at various time
points after administration by determination of radioactivity using a
gamma-counter. The concentrations were reported as percentage of dose /
g tissue. These values were converted to concentrations in ng/ml
assuming a density of 1 g/ml for all tissues except for bone for which a
density of 1.5 g/ml was assumed (as in Ref. <a href="#id_5-references">Baxter 1994</a>).</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="section level3">
<h3 id="model-parameters-and-assumptions">2.3 Model Parameters and
Assumptions<a id="model-parameters-and-assumptions"></a><a class="anchor" aria-label="anchor" href="#model-parameters-and-assumptions"></a>
</h3>
<div class="section level4">
<h4 id="absorption">2.3.1 Absorption<a class="anchor" aria-label="anchor" href="#absorption"></a>
</h4>
<p>There is no absorption process since BAY 79-4620 was administered
intravenously.</p>
</div>
<div class="section level4">
<h4 id="distribution">2.3.2 Distribution<a class="anchor" aria-label="anchor" href="#distribution"></a>
</h4>
<p>The standard lymph and fluid recirculation flow rates and the
standard vascular properties of the different tissues (hydraulic
conductivity, pore radii, fraction of flow via large pores) from PK-Sim
were used. BAY 79-4620, among other compounds, has been used to identify
these lymph and fluid recirculation flow rates used in PK-Sim (<a href="#id_5-references">Niederalt 2018</a>).</p>
<p>A standard PK-Sim model was used without an additional tumor organ -
in contrast to the model which has been used in Ref. (<a href="#id_5-references">Niederalt 2018</a>). It was assumed that BAY
79-4620 is not cross-reactive to murine CA IX, i.e. there is no
drug-target binding due to the neglect of tumor tissue in the present
PK-Sim standard model (again in contrast to the model used in Ref. (<a href="#id_5-references">Niederalt 2018</a>)).</p>
</div>
<div class="section level4">
<h4 id="metabolism-and-elimination">2.3.3 Metabolism and Elimination<a class="anchor" aria-label="anchor" href="#metabolism-and-elimination"></a>
</h4>
<p>The FcRn mediated clearance present in the standard PK-Sim model was
used as only clearance process (in contrast to the model used in Ref.
(<a href="#id_5-references">Niederalt 2018</a>), where there is an
additional target mediated clearance process in tumor tissue). The
affinity to FcRn in the endosomal space was fitted to the PK data. The
same value as fitted in Ref. (<a href="#id_5-references">Niederalt
2018</a>) was used since the contribution from target mediated clearance
was small.</p>
</div>
<div class="section level4">
<h4 id="tissue-concentrations">2.3.4 Tissue Concentrations<a class="anchor" aria-label="anchor" href="#tissue-concentrations"></a>
</h4>
<p>For the comparison with experimental data the parameters
<code>Fraction of blood for sampling</code> used in the Observer for the
tissue concentrations were set for all organs to 0.18 for comparison
with tissue dissection data and to 0.42 for comparison with
autoradiography data according to the fit results (across compounds) in
Ref. (<a href="#id_5-references">Niederalt 2018</a>). (The parameter
<code>Fraction of blood for sampling</code> specifies residual blood in
tissue as ratio of blood volume contributing to the measured tissue
concentration to the total in vivo capillary blood volume.)</p>
<p>In the present evaluation report, the experimental intestine
concentrations from the tissue dissection study were compared to
simulated organ concentrations for small and large intestine separately
in the goodness of fit plots as well as in the concentration-time
profile plot.</p>
</div>
<div class="section level4">
<h4 id="automated-parameter-identification">2.3.5 Automated Parameter Identification<a class="anchor" aria-label="anchor" href="#automated-parameter-identification"></a>
</h4>
<p>The table shows the parameter values that were specified in the model
based on the parameter identification reported in Ref. (<a href="#id_5-references">Niederalt 2018</a>), and which were not included
in the PK-Sim database since version 7.1.</p>
<table style="width:100%;" class="table">
<colgroup>
<col width="74%">
<col width="18%">
<col width="7%">
</colgroup>
<thead><tr class="header">
<th>Model Parameter</th>
<th>Optimized Value</th>
<th>Unit</th>
</tr></thead>
<tbody>
<tr class="odd">
<td><code>Kd(FcRn) in endosomal space</code></td>
<td>12.7</td>
<td>µmol/L</td>
</tr>
<tr class="even">
<td>
<code>Fraction of blood for sampling</code> (all organs) - for
comparison with tissue dissection data</td>
<td>0.18</td>
<td></td>
</tr>
<tr class="odd">
<td>
<code>Fraction of blood for sampling</code> (all organs) - for
comparison with autoradiography data</td>
<td>0.42</td>
<td></td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="section level2">
<h2 id="results-and-discussion">3 Results and Discussion<a id="results-and-discussion"></a><a class="anchor" aria-label="anchor" href="#results-and-discussion"></a>
</h2>
<p>The PBPK model for BAY 79-4620 was evaluated with blood and tissue PK
data from mice.</p>
<p>These PK data have been used together with PK data from 5 other
compounds to simultaneously identify parameters during the development
of the generic model for proteins and large molecules in PK-Sim (<a href="#id_5-references">Niederalt 2018</a>).</p>
<p>The fitted dissociation constant for binding to FcRn in the endosomal
space is rather high compared to usual dissociation constants. This
might reflect a lowered affinity to FcRn due to the conjugation of the
toxophore or alternatively is a surrogate for a clearance process not
represented in the model.</p>
<p>The next sections show:</p>
<ol style="list-style-type: decimal">
<li>the final model parameters for the building blocks: <a href="#id_31-final-input-parameters">Section 3.1</a>.</li>
<li>the overall goodness of fit: <a href="#id_32-diagnostics-plots">Section 3.2</a>.</li>
<li>simulated vs. observed concentration-time profiles for the clinical
studies used for model building and for model verification: <a href="#id_33-concentration-time-profiles">Section 3.3</a>.</li>
</ol>
<div class="section level3">
<h3 id="final-input-parameters">3.1 Final input parameters<a id="final-input-parameters"></a><a class="anchor" aria-label="anchor" href="#final-input-parameters"></a>
</h3>
<p>The compound parameter values of the final PBPK model are illustrated
below.</p>
<div class="section level4">
<h4 id="compound-bay794620">Compound: BAY794620<a class="anchor" aria-label="anchor" href="#compound-bay794620"></a>
</h4>
<div class="section level5">
<h5 id="parameters">Parameters<a class="anchor" aria-label="anchor" href="#parameters"></a>
</h5>
<table class="table">
<colgroup>
<col width="35%">
<col width="10%">
<col width="38%">
<col width="9%">
<col width="5%">
</colgroup>
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
<th>Value Origin</th>
<th>Alternative</th>
<th>Default</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Solubility at reference pH</td>
<td>99999 mg/l</td>
<td>Other-/Dummy value not used in the simulation</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="even">
<td>Reference pH</td>
<td>7</td>
<td>Other-/Dummy value not used in the simulation</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Lipophilicity</td>
<td>-5 Log Units</td>
<td>Other-/Dummy value not used in the simulation</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="even">
<td>Fraction unbound (plasma, reference value)</td>
<td>1</td>
<td>Other-Assumption</td>
<td>Measurement</td>
<td>True</td>
</tr>
<tr class="odd">
<td>Is small molecule</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Molecular weight</td>
<td>152000 g/mol</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>Plasma protein binding partner</td>
<td>Unknown</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr class="even">
<td>Radius (solute)</td>
<td>0.00534 µm</td>
<td>Publication-Taylor1984</td>
<td></td>
<td></td>
</tr>
<tr class="odd">
<td>Kd (FcRn) in endosomal space</td>
<td>12.7 µmol/l</td>
<td>Parameter Identification</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="calculation-methods">Calculation methods<a class="anchor" aria-label="anchor" href="#calculation-methods"></a>
</h5>
<table class="table">
<thead><tr class="header">
<th>Name</th>
<th>Value</th>
</tr></thead>
<tbody>
<tr class="odd">
<td>Partition coefficients</td>
<td>PK-Sim Standard</td>
</tr>
<tr class="even">
<td>Cellular permeabilities</td>
<td>PK-Sim Standard</td>
</tr>
</tbody>
</table>
</div>
<div class="section level5">
<h5 id="processes">Processes<a class="anchor" aria-label="anchor" href="#processes"></a>
</h5>
</div>
</div>
</div>
<div class="section level3">
<h3 id="diagnostics-plots">3.2 Diagnostics Plots<a id="diagnostics-plots"></a><a class="anchor" aria-label="anchor" href="#diagnostics-plots"></a>
</h3>
<p>Below you find the goodness-of-fit visual diagnostic plots for the
PBPK model performance of all data used presented in <a href="#PK-data">Section 2.2.2</a>.</p>
<p>The first plot shows observed versus simulated plasma concentration,
the second weighted residuals versus time.</p>
<p><a id="table-3-1"></a></p>
<p><strong>Table 3-1: GMFE for Goodness of fit plot for concentration in
blood and tissues</strong></p>
<table class="table">
<thead><tr class="header">
<th align="left">Group</th>
<th align="left">GMFE</th>
</tr></thead>
<tbody>
<tr class="odd">
<td align="left">BAY 79-4620 - autoradiography</td>
<td align="left">1.48</td>
</tr>
<tr class="even">
<td align="left">BAY 79-4620 - tissue dissection</td>
<td align="left">1.62</td>
</tr>
<tr class="odd">
<td align="left">All</td>
<td align="left">1.53</td>
</tr>
</tbody>
</table>
<p><br><br></p>
<p><a id="figure-3-1"></a></p>
<p><img src="images/006_section_results-and-discussion/008_section_diagnostics-plots/2_gof_plot_predictedVsObserved.png"></p>
<p><strong>Figure 3-1: Goodness of fit plot for concentration in blood
and tissues</strong></p>
<p><br><br></p>
<p><a id="figure-3-2"></a></p>
<p><img src="images/006_section_results-and-discussion/008_section_diagnostics-plots/3_gof_plot_residualsOverTime.png"></p>
<p><strong>Figure 3-2: Goodness of fit plot for concentration in blood
and tissues</strong></p>
<p><br><br></p>
</div>
<div class="section level3">
<h3 id="concentration-time-profiles">3.3 Concentration-Time Profiles<a id="ct-profiles"></a><a class="anchor" aria-label="anchor" href="#concentration-time-profiles"></a>
</h3>
<p>Simulated versus observed concentration-time profiles of all data
listed in <a href="#PK-data">Section 2.2.2</a> are presented below.</p>
<p><a id="figure-3-3"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/1_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-3: Blood - lin scale</strong></p>
<p><br><br></p>
<p><a id="figure-3-4"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/2_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-4: Blood - log scale</strong></p>
<p><br><br></p>
<p><a id="figure-3-5"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/3_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-5: Lung</strong></p>
<p><br><br></p>
<p><a id="figure-3-6"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/4_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-6: Kidney</strong></p>
<p><br><br></p>
<p><a id="figure-3-7"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/5_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-7: Skin</strong></p>
<p><br><br></p>
<p><a id="figure-3-8"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/6_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-8: Muscle</strong></p>
<p><br><br></p>
<p><a id="figure-3-9"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/7_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-9: Spleen</strong></p>
<p><br><br></p>
<p><a id="figure-3-10"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/8_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-10: Liver</strong></p>
<p><br><br></p>
<p><a id="figure-3-11"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/9_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-11: Heart</strong></p>
<p><br><br></p>
<p><a id="figure-3-12"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/10_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-12: Fat</strong></p>
<p><br><br></p>
<p><a id="figure-3-13"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/11_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-13: Brain</strong></p>
<p><br><br></p>
<p><a id="figure-3-14"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/12_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-14: Stomach</strong></p>
<p><br><br></p>
<p><a id="figure-3-15"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/13_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-15: Pancreas</strong></p>
<p><br><br></p>
<p><a id="figure-3-16"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/14_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-16: Small Intestine</strong></p>
<p><br><br></p>
<p><a id="figure-3-17"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/15_time_profile_plot_BAY_79_4620_BAY794620_autoradiography.png"></p>
<p><strong>Figure 3-17: Ovaries</strong></p>
<p><br><br></p>
<p><a id="figure-3-18"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/16_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-18: Blood - lin scale</strong></p>
<p><br><br></p>
<p><a id="figure-3-19"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/17_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-19: Blood - log scale</strong></p>
<p><br><br></p>
<p><a id="figure-3-20"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/18_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-20: Lung</strong></p>
<p><br><br></p>
<p><a id="figure-3-21"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/19_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-21: Kidney</strong></p>
<p><br><br></p>
<p><a id="figure-3-22"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/20_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-22: Bone</strong></p>
<p><br><br></p>
<p><a id="figure-3-23"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/21_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-23: Muscle</strong></p>
<p><br><br></p>
<p><a id="figure-3-24"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/22_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-24: Spleen</strong></p>
<p><br><br></p>
<p><a id="figure-3-25"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/23_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-25: Liver</strong></p>
<p><br><br></p>
<p><a id="figure-3-26"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/24_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-26: Heart</strong></p>
<p><br><br></p>
<p><a id="figure-3-27"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/25_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-27: Fat</strong></p>
<p><br><br></p>
<p><a id="figure-3-28"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/26_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-28: Brain</strong></p>
<p><br><br></p>
<p><a id="figure-3-29"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/27_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-29: Stomach</strong></p>
<p><br><br></p>
<p><a id="figure-3-30"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/28_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-30: Pancreas</strong></p>
<p><br><br></p>
<p><a id="figure-3-31"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/29_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-31: Intestine</strong></p>
<p><br><br></p>
<p><a id="figure-3-32"></a></p>
<p><img src="images/006_section_results-and-discussion/009_section_ct-profiles/30_time_profile_plot_BAY_79_4620_BAY794620_tissueDissection.png"></p>
<p><strong>Figure 3-32: Ovaries</strong></p>
<p><br><br></p>
</div>
</div>
<div class="section level2">
<h2 id="conclusion">4 Conclusion<a id="conclusion"></a><a class="anchor" aria-label="anchor" href="#conclusion"></a>
</h2>
<p>The herein presented PBPK model overall adequately describes the
pharmacokinetics of BAY 79-4620 in mice. The tissue concentrations from
the low dose tissue dissection study (dose approximately 0.025 mg/kg)
are similarly well described as the tissue concentrations from the
autoradiography study (dose 1.25 mg/kg), with the exception of the late
concentrations at 168 h after administration from the tissue dissection
study which are underestimated by the model. The largest deviations
between measured and simulated concentration-time profiles are observed
for spleen concentrations which are overestimated by the model and brain
concentrations which are underestimated.</p>
<p>The PK data had been used during the development of the generic large
molecule PBPK model in PK-Sim (<a href="#id_5-references">Niederalt
2018</a>) together with PK data from 5 other compounds (7E3, CDA1, dAb2,
MEDI-524 &amp; MEDI-524-YTE).</p>
</div>
<div class="section level2">
<h2 id="references">5 References<a id="main-references"></a><a class="anchor" aria-label="anchor" href="#references"></a>
</h2>
<p><strong>Baxter 1994</strong> Baxter LT, Zhu H, Mackensen DG, Jain RK.
Physiologically based pharmacokinetic model for specific and nonspecific
monoclonal antibodies and fragments in normal tissues and human tumor
xenografts in nude mice. Cancer research. 1994 Mar; 54(6):1517-1528.</p>
<p><strong>Dall’Acqua 2006</strong> Dall’Acqua WF, Kiener PA, Wu H.
Properties of human IgG1s engineered for enhanced binding to the
neonatal Fc receptor (FcRn). J Biol Chem. 2006 Aug; 281(33):23514-23524.
doi: 10.1074/jbc.M604292200.</p>
<p><strong>Garg 2007</strong> Garg A, Balthasar JP.
Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue
kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet
Pharmacodyn. 2007 Jul; 34(5):687-709. doi:
10.1007/s10928-007-9065-1.</p>
<p><strong>Garg 2009</strong> Garg A, Balthasar J. Investigation of the
influence of FcRn on the distribution of IgG to the brain. AAPS J. 2009
July; 11(3):553-557. doi: 10.1208/s12248-009-9129-9.</p>
<p><strong>Lobo 2004</strong> Lobo ED, Hansen R J, Balthasar JP.
Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci. 2004
Nov;93(11):2645-2668. doi: 10.1002/jps.20178.</p>
<p><strong>Niederalt 2018</strong> Niederalt C, Kuepfer L, Solodenko J,
Eissing T, Siegmund HU, Block M, Willmann S, Lippert J. A generic whole
body physiologically based pharmacokinetic model for therapeutic
proteins in PK-Sim. J Pharmacokinet Pharmacodyn. 2018 Apr;45(2):235-257.
doi: 10.1007/s10928-017-9559-4.</p>
<p><strong>Petrul 2012</strong> Petrul HM, Schatz CA, Kopitz CC, Adnane
L, McCabe TJ, Trail P, Ha S, Chang YS, Voznesensky A, Ranges G,
Tamburini PP. Therapeutic mechanism and efficacy of the antibody–drug
conjugate BAY 79-4620 targeting human carbonic anhydrase 9. Molecular
Cancer Therapeutics. 2012 Feb;11(2):340-349. doi:
10.1158/1535-7163.MCT-11-0523.</p>
<p><strong>Reilly 2005</strong> Reilley S, Wenzel E, Reynolds L, Bennett
B, Patti JM, Hetherington S. Open-label, dose escalation study of the
safety and pharmacokinetic profile of tefibazumab in healthy volunteers.
Antimicrob Agents Chemother. 2005 Mar;49(3):959–962. doi:
10.1128/AAC.49.3.959-962.2005.</p>
<p><strong>Sepp 2015</strong> Sepp A, Berges A, Sanderson A, Meno-Tetang
G. Development of a physiologically based pharmacokinetic model for a
domain antibody in mice using the two-pore theory. J Pharmacokinet
Pharmacodyn. 2015 Jan;42(2):97-109. doi: 10.1007/s10928-014-9402-0.</p>
<p><strong>Taylor 1984</strong> Taylor AE, Granger DN. Exchange of
macromolecules across the microcirculation. Handbook of Physiology -
Cardiovascular System. Microcirculation (Eds. Renkin EM and Michel CC.
Bethesda, MD, American Physiological Society). 1984; Vol. 4(Pt
2):467–520.</p>
<p><strong>Taylor 2008</strong> Taylor CP, Tummala S, Molrine D,
Davidson L, Farrell RJ, Lembo A, Hibberd PL, Lowy I, Kelly CP.
Open-label, dose escalation phase I study in healthy volunteers to
evaluate the safety and pharmacokinetics of a human monoclonal antibody
to Clostridium difficile toxin A. Vaccine. 2008 Jun;26(27-28):3404–3409.
doi: 10.1016/j.vaccine.2008.04.042.</p>
<p><strong>Tsuji 1983</strong> Tsuji A, Yoshikawa T, Nishide K, Minami
H, Kimura M, Nakashima E, Terasaki T, Miyamoto E, Nightingale CH, Yamana
T. Physiologically based pharmacokinetic model for beta-lactam
antibiotics I: tissue distribution and elimination in rats. J Pharm Sci.
1983 Nov;72(11):1239-1252. doi: 10.1002/jps.2600721103.</p>
<p><strong>Zhou 2003</strong> Zhou J, Johnson JE, Ghetie V, Ober RJ,
Ward ES. Generation of mutated variants of the human form of the MHC
class I-related receptor, FcRn, with increased affinity for mouse
immunoglobulin G. J Mol Biol. 2003 Sep;332(4):901-913. doi:
10.1016/s0022-2836(03)00952-5.</p>
</div>
  </main><aside class="col-md-3"><nav id="toc" aria-label="Table of contents"><h2>On this page</h2>
    </nav></aside>
</div>



    <footer><div class="pkgdown-footer-left">
  <p>Developed by Pierre Chelle.</p>
</div>

<div class="pkgdown-footer-right">
  <p>Site built with <a href="https://pkgdown.r-lib.org/" class="external-link">pkgdown</a> 2.1.3.</p>
</div>

    </footer>
</div>





  </body>
</html>
